Novel therapeutic approaches for chronic kidney disease due to glomerular disorders

Improved understanding of glomerular disease mechanisms over the past decade has led to the emergence of new and targeted therapeutic strategies for chronic kidney disease (CKD). Most promising among these are the administration of recombinant mutated human angiopoietin-like 4, sialic acid-related s...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Renal physiology Vol. 311; no. 1; pp. F63 - F65
Main Authors Del Nogal-Avila, Maria, Donoro-Blazquez, Hector, Saha, Manish K, Marshall, Caroline B, Clement, Lionel C, Macé, Camille E A, Chugh, Sumant S
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.07.2016
Subjects
Angiopoietin-like 4 Protein
Angiopoietins - therapeutic use
Animals
Clinical trials
Drugs
Humans
Kidney diseases
Kidney Glomerulus - pathology
Medical treatment
Mutation
Proteinuria - drug therapy
Renal Insufficiency, Chronic - drug therapy
Renal Insufficiency, Chronic - pathology
Toxicity
drugs
chronic kidney disease
proteinuria
Online AccessGet full text

Cover

More Information
Summary:Improved understanding of glomerular disease mechanisms over the past decade has led to the emergence of new and targeted therapeutic strategies for chronic kidney disease (CKD). Most promising among these are the administration of recombinant mutated human angiopoietin-like 4, sialic acid-related sugars that induce sialylation in vivo, compounds related to Bis-T-23, and immune depletion of the soluble urokinase receptor from the circulation. Taking these therapeutic strategies into clinical trials will be the first step away from repurposed and relatively toxic drugs currently used for treating kidney disease.
ISSN:1931-857X
1522-1466
DOI:10.1152/ajprenal.00245.2016